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AgingAging has been associatedwith adverse ﬁbrosis. Here we formulate a new hypothesis and present new evidence
that unresponsiveness of mesenchymal stem cells (MSC) and ﬁbroblasts to transforming growth factor beta
(TGF-β), due to reduced expression of TGF-β receptor I (TβRI), provides a foundation for cardiac ﬁbrosis in the
aging heart via two mechanisms. 1) TGF-β promotes expression of Nanog, a transcription factor that retains
MSC in a primitive state. InMSC derived from the aging heart, Nanog expression is reduced and thereforeMSC grad-
ually differentiate and the number ofmesenchymal ﬁbroblasts expressing collagen increases. 2) As TGF-β signaling
pathway components negatively regulate transcription ofmonocyte chemoattractant protein-1 (MCP-1), a reduced
expression of TβRI prevents aging mesenchymal cells from shutting down their own MCP-1 expression. Elevated
MCP-1 levels that originated from MSC attract transendothelial migration of mononuclear leukocytes from blood
to the tissue. MCP-1 expressed by mesenchymal ﬁbroblasts promotes further migration of monocytes and T lym-
phocytes away from the endothelial barrier and supports the monocyte transition into macrophages and ﬁnally
intomyeloid ﬁbroblasts. Bothmyeloid andmesenchymal ﬁbroblasts contribute to ﬁbrosis in the aging heart via col-
lagen synthesis. This article is part of a Special Issue entitled "Myocyte-Fibroblast Signalling in Myocardium ".
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Secretion of extracellularmatrix (ECM) proteins can be both adaptive
and deleterious. Various pathological conditions trigger ECM (mostly
collagens) deposition in the heart. A sudden loss of cardiomyocytes
from a myocardial infarction (MI) causes activation of replace-
ment/reparative ﬁbrosis, where collagens substitute for necrotic
cardiomyocytes and form a scar to preserve structural integrity of
the heart [1]. In other pathophysiological conditions (in the absence
of infarction) such as pressure overload [2], cardiomyopathy [3], and
diabetes [4] adverse ﬁbrosis has been observed as an interstitial or
perivascular deposition of ECM. Interestingly, normal aging has been as-
sociated with progressive ﬁbrosis [5], but the mechanism responsible
for increased collagen content in the aging heart may bemore complex
than initially thought.
In the heart, both reparative scar formation [6] and adverse reactive
ﬁbrosis [7,8] are associated with pathophysiologic factors mediated by
inﬂammation. Tissue inﬂammation is initiated by recruitment of leuko-
cytes from blood through the venular endothelial barrier. This process
can be modulated by endothelial and stromal cells. The endothelium
regulates leukocyte recruitment by modulating expression of speciﬁc
adhesion molecules that attract leukocytes and promote their adhesion
to the endothelial cell border [9].
Evidence also suggests that other cells such asﬁbroblasts [10,11] and
macrophages [12]may play important roles in leukocyte recruitment as
well. It has been demonstrated in in vitro studies thatﬁbroblasts derived
from chronically inﬂamed tissue supported leukocyte diapedesis [13], in
contrast to ﬁbroblasts derived from healthy donors [14]. The described
effect was attributed to the presence of MCP-1 [13]. MCP-1 is a strong
monocyte and T lymphocyte chemoattractant [15]. Elevated expression
levels of MCP-1 and CCR2 (an MCP-1 receptor) has been reported in
various diseases characterized by inﬂammation such as rheumatoid
arthritis, multiple sclerosis and asthma [16]. In this communication, we
focus on the role of inﬂammatory signaling between different ﬁbroblast
precursors as the source of chronic progressive cardiac ﬁbrosis.
2. Fibrosis as a result of chemokine dysregulation; the myeloid
(CD45+) ﬁbroblast
CD45+ ﬁbroblasts of myeloid origin have been identiﬁed in various
models of adverse ﬁbrosis studied in our laboratory. When we examine
cardiac ﬁbrosis as a consequence of non infarctive brief daily coronary
occlusion (ischemia/reperfusion cardiomyopathy, I/RC) [7] or angioten-
sin II infusion [17] and in a chronic condition such as aging [5], all
models were characterized by the presence of CD45+ myeloid ﬁbro-
blasts in the myocardium. Fibroblasts of myeloid origin are spindle-
shaped and smaller than structural (mesenchymal)ﬁbroblasts; they ex-
press collagen type I and alpha-smooth muscle actin (α-SMA), and are
highly proliferative [7]. The presence of these cells in the heart relies
on expression ofMCP-1 since genetic deletion ofMCP-1 [17,18] or its re-
ceptor [19] prevents development of cardiacﬁbrosis. Our in vitro studies
using human monocytes and a cardiac endothelial layer conﬁrmed that
in response toMCP-1, monocytes and T cells migrate through the endo-
thelial barrier [20,21] and after transmigration themonocytes transition
into myeloid ﬁbroblasts. This transition is dependent on Th1 and Th2
lymphocyte induction and secretion of speciﬁc lymphokines and re-
quires transendothelial migration [5]. The role of MCP-1 in ﬁbrosis
has been studied by other laboratories aswell. Its importance in thepro-
motion of ﬁbrosis in various models and organs has been conﬁrmed in
kidney [22], liver [23] and lung [24].
In the acute models of ﬁbrosis following daily ischemia and reperfu-
sion [25] or angiotensin II infusion [17], expression of MCP-1 was ele-
vated for up to 14 days and then its level was reduced to baseline
even in the presence of continuing stimulus [25], suggesting that an
MCP-1 repressing mechanism was activated. Despite the continued in-
sult, the number of myeloid ﬁbroblasts was also gradually reduced[17] andﬁbrosis did not progress [25]. Suppression ofMCP-1 production
correlates with induction of de novo TGF-β synthesis [6]; moreover,
TGF-β-dependent activation of Smad 3 attenuatesMCP-1 transcription-
al activation [26]. TGF-β null mice, on the other hand, are characterized
by an excessive inﬂammation and massive and unattenuated inﬁltra-
tion of leukocytes [27,28]. Genetic deletion of thrombospondin-1, a pro-
tein that determines TGF-β biological activity, resulted in prolonged
post-infarction inﬂammation [29], implying that TGF-β plays a crucial
role in resolution of inﬂammation.
In contrast to acutemodels, in a chronicmodel, aging, we have dem-
onstrated a progressively elevated MCP-1 expression starting in middle
age (14 months of age) accompanied by an increasing number of mye-
loid ﬁbroblasts [5]. This indicates that in the aging heart the factor that
suppresses MCP-1 expression is not operant. As a result, progressive
ﬁbrosiswas observedwith aging accompanied by a progressive increase
in T lymphocytes (CD3) and the Th2 lymphokine (IL-13) [5]. All of these
markers are compatible with persistence ofMCP-1 induced chemotaxis.
Interestingly, elevated recruitment of CD45+ cells in aged mice was
observed not only in the heart [5] but also in the liver [30], kidney [31]
and lung [32] suggesting perhaps a common mechanism behind this
phenomenon.3. Aberrant MSC differentiation in aging; role of reduced
TGF-β responsiveness
Our studies of ﬁbrosis in aging, however, also uncovered another dis-
tinct class of ﬁbroblasts.We identiﬁed these ﬁbroblasts as CD44+CD45neg
cells arising from mesenchymal stem cells (MSC) of non-myeloid origin
[33]. We have found that the number of these cells progressively in-
creases in the agingmyocardiumand concomitantlywith ageprogression
a higher number of these cells differentiate into collagen producing ﬁbro-
blasts but not myoﬁbroblasts [33]. These ﬁbroblasts were larger than the
myeloid ﬁbroblasts and were CD45neg. In contrast to the myeloid ﬁbro-
blasts, they did not become myoﬁbroblasts (i.e. they were α-SMA nega-
tive). These ﬁbroblasts appeared to emanate from the endogenous MSC
found in the heart thatwehave previously implicated as themajor source
ofﬁbroblasts formyocardial scar formation afterMI [34]. In the heart, car-
diacMSC are biased toward a ﬁbroblast lineage [34] although theymain-
tain their plasticity and ability to differentiate into other lineages as well
(in vitro) [35]. In the aging heart, MSC are dysregulated and demonstrate
abnormalities in lineage choice as well as a defect in conversion of ﬁbro-
blasts tomyoﬁbroblasts [36]. This latter abnormality results in the poorer
quality scars found after MI in aging mice [37–39].
We have examined the mechanism by which resistance to TGF-β
might inﬂuence the aberrant function of MSC in the aging heart.
Multipotency of these stem cells is maintained mostly by Nanog [40],
a transcription factor that is associated with various proteins in repres-
sion complexes, which controls other genes' transcription and prevents
differentiation [41]. Nanog expression is directly activated by various
factors, including TGF-β [42,43]. TGF-β signals via two serine/thereonine
kinase receptors: type I receptor (TβRI) and type II receptor (TβRII) [44].
Three types of TβRI have been identiﬁed: activin like kinase (ALK) 1, 2
and 5 [45–47]. The TβRI in MSC and mesenchymal ﬁbroblasts described
below has been identiﬁed as ALK5 [36].
Interestingly, MSC isolated from 30-month old hearts display a re-
duced expression of TβRI (Fig. 1A) and therefore their TGF-β respon-
siveness is diminished. Concomitantly with reduced TβRI expression
the Nanog level was reduced by ~80% in aged cardiac MSC compared
to young controls (Fig. 1B, C left panel). Since TGF-β downregulates ex-
pression of MCP-1 [26] by controlling the activity of AP-1, a transcrip-
tion factor involved in MCP-1 transcriptional induction, we decided to
examine MCP-1 mRNA levels in MSC derived from young and aged
hearts. We found that as MCP-1 mRNA expression increases with age,
the Nanog transcript level proportionally declined (Fig. 1B, C). Thus, de-
fective TGF-β signaling appeared to result in increasedMSC to ﬁbroblast
Fig. 1. The inﬂammatory phenotype of MSC derived from aged hearts concurs with their
reduced expression of TβRI and Nanog. A. TβRI mRNA expression in MSC derived from
young and aged hearts. n = 3, 3 for young and aged mouse hearts from C57BL/6.
p = 0.053 evaluated by Student's t test. B. Expression of Nanog and MCP-1 transcripts
in MSC derived from 3-, 14- and 24–30-month old mice. n = 5, 4, 5 indicate number of
donor mice per age group starting from the youngest. C. Tables show Nanog (left) and
MCP-1 (right) expression with corresponding statistical analysis. mRNA levels were
examined by qPCR performed on a CFX 96 Real Time PCR Detection System using SYBR
green technology. Primers were validated according to MIQE quidelines [103]. Gene
expression was normalized to the level of an endogenous reference (Hprt). B and C are
two different representations of the same experiments. * denotes p b 0.05 compared to
control sample as analyzed by ANOVA. The data for Nanog expression is modiﬁed with
permission from Cieslik K.A., Trial J., Entman M.L. Defective myoﬁbroblast formation
from mesenchymal stem cells in the aging murine heart: Rescue by activation of the
AMPK pathway. The American Journal of Pathology (2011), 179, 1792-1806.
Fig. 2. Inhibition of TβRI activity in MSC derived from young mouse hearts resulted in a
proinﬂammatory phenotype and reduction of Nanog levels. mRNA levels of Nanog and
MCP-1 expression in MSC treated with or without 500 nM LY364947 (inhibitor) for
21 days. Cells derived from 4 different animals were used in 4 independent experiments.
Gene expressionwas normalized to the level of an endogenous reference (Hprt). * denotes
p b 0.05 compared to control sample as analyzed by Student's t test.
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the next section.3.1. Consequences of loss of TGF-β responsiveness
3.1.1. Nanog reduction
A reduced level of Nanog may allowMSC escape from an undifferen-
tiated state since it has been demonstrated that a low level of Nanog
correlates with increased cell differentiation [48] and we observed an
elevated number of CD44+CD45neg ﬁbroblast precursors in the aged
myocardium [33]. To examine further the role of reduced TGF-β respon-
siveness, a potential culprit in aberrant MSC conduct, we subjected MSC
derived fromyounghearts to chronic inhibition of TβRI by supplementing
their culturemediumwith a TβRI kinase inhibitor (LY364947). TβRI inhi-
bition in young cells resembled the scenario in aging presented in Fig. 1B
and C: Nanog expression was reduced (Fig. 2).
In our quest to understand the biology of cardiac MSC in aging, we
challenged the multipotentiality of these cells by subjecting them to
adipocytic, chondrocytic and osteogenic differentiation programs. As
TGF-β, and more speciﬁcally activated Smad3, negatively controls adi-
pogenesis [49] it seems logical that reduced TGF-β responsivenesswould increase MSC “sensitivity” to adipogenic signals. These abnor-
malities are associated in vivo with elevated insulin levels [33]. Thus
TGF-β plays a crucial role in maintaining the MSC primitive state and
prevents skewing into lineages other than the “default” ﬁbroblast.
Abnormal stem cell differentiation with aging has been reported in
satellite cells, mouse hematopoietic stem cells and bone marrow MSC
[50,51].
3.1.2. Failure of MCP-1 suppression
As discussed above, TGF-β exerts an important anti-inﬂammatory
role which features suppression of chemokines [6,26,29]. This property
also appears to be pertinent to MSC and their progeny. The aging MSC
fail to suppress MCP-1 production despite ample supplies of cardiac
TGF-β (Figs. 1B, C), and similarly, inhibition of TβRI in MSC derived
from young hearts also results in elevated expression of MCP-1 (Fig. 2).
4. TGF-β resistance and progressive ﬁbrosis in the aging heart — an
apparent paradox
TGF-β is a canonical growth factor that promotes extracellular pro-
tein synthesis [52]. Its role in ﬁbrosis has been well established in the
heart, lung, kidney, and liver [53–56], and inhibition of TGF-β signaling
has been shown to reduce adverse ﬁbrosis in many models [55,56]. The
ﬁnding that TGF-β resistance actually enhances ﬁbrosis by several
mechanisms in the aging heart involving ﬁbroblast precursors of two
separate origins has afforded us important insights into the signaling
mechanisms promoting this critical paradox and a better understanding
of the emergence of chronic ongoing ﬁbrosis.
Changes of TGF-β signaling have been associated with age-related
osteoarthritis and skin photodamage. The former has been linked to a
switch from ALK5 to preferential ALK1 mediated signaling [57], and
the latter showed reduced expression of TβRII [58]. Both mechanisms
link reduced Smad2/3 mediated signaling with aging similar to our
aging heart model [36].
4.1. MSC-derived ﬁbroblast
The ﬁrst signaling relates to the species of ﬁbroblasts found in the
aging heart that arise from TGF-β resistant MSC described above [36].
Because they retain the TGF-β resistance [36], these ﬁbroblasts do not
becomemyoﬁbroblasts and appear to be associated with the interstitial
ﬁbrosis seen in aging [33]. One potential mechanism relates to the fact
that loss of TGF-β induced Nanog suppression invites an increased
Fig. 3. Fibroblasts derived from aged MSC present an inﬂammatory phenotype.
A. Increased synthesis of MCP-1 mRNA and protein in ﬁbroblasts derived from
30 month old MSC mice (aged) compared with young controls from 3 month old mice
(young). Gene expression was normalized to the level of an endogenous reference
(Hprt). mRNA was measured in quiescent ﬁbroblasts. Expression of protein secreted
into the culture mediumwithin 24 h was measured on RayBio Mouse Cytokine Antibody
Array and normalized to the positive control. * denotes p b 0.05 (Student's t test).
B. Elevated level of superoxide inﬁbroblasts derived from 30 month old cardiacMSC visu-
alized via MitoSox. n = 3, 3 for young and aged donors.
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population. Our studies also suggest a role for signaling via farnesyl
transferase and ERK in the TGF-β resistant ﬁbroblasts [33]. Others
have also reported that α-SMA deﬁciency has been previously noted
as a factor associatedwith enhanced ﬁbrosis in the lung [59] and kidney
[60].
4.2. Myeloid ﬁbroblast
The second signaling event relates to the myeloid ﬁbroblasts
responding to a persistence of MCP-1 expression that normally abates
in other more acute models of adverse ﬁbrosis [8,20]. In the aging
model, the myeloid ﬁbroblast expressed α-SMA but α-SMA expression
was not evident in the mesenchymal ﬁbroblast [33]. Therefore TGF-β
resistance was conﬁned to the endogenous MSC and their ﬁbroblast
progeny [36]. It suggested the possibility that MSC, or cells arising from
them, might be an important factor in the persistence of MCP-1 produc-
tion, and promote formation of myeloid ﬁbroblasts.
4.3. Inﬂammatory signaling
Both of these ﬁbrosis mechanisms depend on dysregulation of
inﬂammatory signaling very commonly associated with MSC differenti-
ation. Myeloid ﬁbroblasts and MSC differentiation are both potently
regulated by TGF-β, which also inﬂuences monocyte and T lymphocyte
signaling [61,62]. Fibroblasts emanating fromMSCmay increase in num-
ber because of the increased MSC differentiation resulting from Nanog
alterations but are also resistant to TGF-β suppression of a variety of
inﬂammatory cytokines and chemokines. The remainder of this section
begins an investigation of potential mechanisms linking the mecha-
nisms by which ﬁbroblasts of two different origins combine to induce
ﬁbrosis in aging.
4.4. MSC-derived ﬁbroblasts as a source of chronic MCP-1 generation
To further assess the role of TGF-β in cardiac ﬁbrosis in the aging
heart, we analyzed mouse hearts from 3 and 30 month old C57BL/6
mice for TGF-β1 transcript levels by quantitative PCR (qPCR). We
found a modest increase of TGF-β1 in aged hearts (1.19 ± 0.075 in
3 month old versus 2.23 ± 0.43 in 30 month old) that was statistically
signiﬁcant (p = 0.037). TGF-β is present in the uninjured heart mostly
in a latent, inactive form. This latent TGF-β is bound to extracellular
matrix (ECM) and its release from matrix is triggered by various
enzymes [63]. For this potential signaling, TGF-β1 is plentiful in the
aged heart and its release in the bioactive form [64] from the matrix is
via enzymes whose expression is enhanced by IL-13 [65] or MMP9
[64] (which are also elevated in the aged heart [5,66]).
Although TGF-β seems to be essential for development of ﬁbrosis via
induction of ECM protein synthesis [67] and promotion of ﬁbroblast
maturation [68] its role in aging dependent ﬁbrosis may be different
and related to signal alteration via downregulation of the receptor
[58] or switch of preferential effector downstream of the receptor [57].
Next, we examined the expression of MCP-1 transcript and protein
levels in MSC-derived ﬁbroblasts (Fig. 3A). The defect we observed in
aged MSC (Fig. 1B, C right panel) was passed on to their progeny ﬁbro-
blasts; their expression of MCP-1 was elevated by 7 and 4 fold in mRNA
and secreted protein levels respectively when compared to young
controls.
In addition to the failure of TGF-β suppression, several mechanisms
may play roles in the upregulated expression of MCP-1. We hypothe-
sized that reactive oxygen species (ROS) are important in the chronic
induction of MCP-1 in ﬁbroblasts derived from aged MSC based on our
previously demonstrated association between ROS levels and MCP-1
expression [25,69,70]. Analysis of quiescent cultured ﬁbroblasts revealed
an elevated production of superoxide in agedﬁbroblastswhen compared
to young controls (Fig. 3B) suggesting that an altered mitochondrialfunction may be responsible for the defect. However we have not ex-
cluded other pathways that might be involved in this exaggerated
MCP-1 synthesis. Others have shown that the angiotensin II type I
receptor 1 (AT-1) may be involved in MCP-1 induction in a model of
pressure overloaded hearts [71]. Increased local expression of ACE and
AT-1 in the aging heart has been reported by our laboratory before [5].5. Chronicmyocardial ﬁbrosis arises from dysregulation of signaling
between ﬁbroblasts of two distinct origins — the inﬂammatory
ﬁbroblast hypothesis
Our studies demonstrated a major role for the age dependent in-
crease in myeloid ﬁbroblasts in cardiac ﬁbrosis of the aging mouse,
which was likewise accompanied by increases in MCP-1 as well as
myeloid ﬁbroblasts [5]. As opposed to the acute models described
above, this chronic ﬁbrosis was attended by an age-dependent increase
in the presence of myeloid ﬁbroblasts as well as chemokines and lym-
phokines that characterized the signal cascade driving their formation
[5]. The aging model, therefore, represented an opportunity to gain po-
tential insight into ongoing chronic ﬁbrosis in the heart but not present
in the acute models.
We postulated that the chronicmodels involved important dysregu-
lation in a signaling process that ordinarily suppresses inﬂammatory
signaling related to myeloid ﬁbrosis [5]. As described above, studies
had suggested that the ﬁbroblasts mediatingmyocardial scar formation
after ischemia did not arise from myeloid ﬁbroblasts but appeared to
arise from MSC [34]. Subsequent studies demonstrated that these MSC-
derived ﬁbroblasts were progressively abnormal in the aging mouse; as
described above, there was a marked reduction in TGF-β responsiveness
Fig. 4. Proposed mechanism of ﬁbrosis in the aging heart. In the aged heart MSC differen-
tiate into mesenchymal ﬁbroblasts that have reduced TGF-β responsiveness but secrete
elevated levels of MCP-1. MCP-1 enhances monocyte transendothelial migration con-
tributing to an increased number of myeloid ﬁbroblasts in the aged heart. Fibroblasts
of mesenchymal and myeloid origin participate in development of ﬁbrosis in the aging
hearts by producing and depositing collagens. Mo and Mϕ denote monocyte and macro-
phage respectively.
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ity resulted in defects in myoﬁbroblast function manifested both in vivo
and in vitro [36–39]. The pathologic consequence of this with respect to
scar formation is discussed in detail elsewhere [39]. In this report, we
will address the signiﬁcance of TGF-β resistance in MSCs as it affects
inﬂammatory signaling.
Based on these observations we postulate that MCP-1 secreted by
MSC (that are in a perivascular location [72]) attracts the migration of
myeloid leukocytes through an endothelial barrier and promotes leuko-
cyte inﬂux into the tissue via an MCP-1 gradient. A number of experi-
ments indicate an anti-inﬂammatory or immunosuppressive role for
MSC. It has been demonstrated that bone marrow MSC can suppress T
cell [73], B cell [74] and NK cell [75] proliferation. In vitro studies have
demonstrated that humanMSC can induce the generation of regulatory
T cells, a T cell subtype that prevents autoimmunity and maintains im-
mune homeostasis [76]. It is thought that MSC exert their immunosup-
pressive property via secretion of various mediators (for an extensive
review see [77], and that this paracrine effectmay have a potential ther-
apeutic use in inﬂammatory dysregulations such as multiple sclerosis
[78], inﬂammatory bowel disease [79] and diabetes [80]. In fact, several
clinical trials are already completed or ongoing, that study systemic use
ofMSC in immunological disorders (http://clinicaltrials.gov). In parallel,
there are reports describingMSC inhibition of inﬂammatory-dependent
ﬁbrosis in skin [81] and kidney [82] models. From a study byWaterman
et al. it is clear that MSC function can be modulated by external signals
[83], suggesting that the environment of the aging heart may alter the
function of resident MSC.
We hypothesize that MCP-1 released by mesenchymal ﬁbroblasts
promotes the migration of monocytes and T lymphocytes away from
sub-endothelial compartments, as described by McGettrick at el [84],
and their subsequent transition to ﬁbroblasts. Monocytes that migrate
through endothelium differentiate early after a chemoattractive stimu-
lus to M1 (classically) and later to M2 (alternatively) activated macro-
phages [85]. As the M1 response transitions towards the M2 response
the cells start expressing collagen type I (MCP-1 increases expression
of TGF-β and collagen type I in human monocytes [86]) and effectively
become myeloid derived ﬁbroblasts. This process is supported by T
cells that migrate together with monocytes in response to the MCP-1
gradient [5]. Once the T cells are in the tissue, they polarize to Th1
(proinﬂammatory) and Th2 (proﬁbrotic) subtypes. Th2 lymphocytes
promote the transition frommonocytes toM2 alternatively activated
macrophages and ﬁnally to myeloid ﬁbroblasts [87], and Th1 lympho-
cytes activate lysyl oxidase (LOX) 1 and 3, enzymes that crosslinkﬁbrillar
collagen [88]. Thus, it is clear that MCP-1 affects various cells by orches-
trating several processes leading to myeloid dependent ﬁbrosis [5].
The functional relationship between the roles of ﬁbroblasts ofmesen-
chymal andmyeloid origins in the progression of chronic cardiac ﬁbrosis
has been delineated in Fig. 4. The role of the inﬂammatory ﬁbroblast and
its chemokine(s) expression has been suggested in othermodels such as
myocardial infarction (MI) [10], rheumatoid arthritis [11] and skin ﬁbro-
sis [89].
In this review we extensively discuss two types of ﬁbroblasts that
are of mesenchymal and myeloid origins, both of which participate in
adverse ﬁbrosis in aging. Several sources of mesenchymal ﬁbroblasts
other than from resident cardiac MSC have been implicated in the de-
velopment of ﬁbrosis. Epithelial cells that acquire a mesenchymal phe-
notype (EMT) have been shown to contribute to a pool of ﬁbroblasts,
especially under inﬂammatory conditions [90]. Likewise, endothelial
to mesenchymal transition (EndoMT) has been linked to ﬁbrosis [91]
as well as bone marrow MSC [92] and pericytes [93]. Input of these
cells (especially originating from EMT and EndoMT) into ﬁbrosis has
been recently challenged by other scientists based on lack of speciﬁcity
of one of themarker used to characterized these cells, FSP-1 [94,95]. Ad-
ditionally it was demonstrated that these mesenchymal ﬁbroblasts that
originated from various sources mature into myoﬁbroblasts expressing
α-SMA. We have demonstrated that in the aging heart the majority ofmesenchymal ﬁbroblasts are α-SMAneg [33]. Although that does not
exclude the above described cells from contributing to the ﬁbroblast
pool (because the defect in TGF-β signaling may not be restricted only
to resident MSC), our studies demonstrated that the changes seen in
resident MSC recapitulate the abnormalities see in vivo [34,39].6. Possible therapeutic strategy
Whether advanced ﬁbrosis can be reversed is controversial. It has
been demonstrated that the collagen content of the left ventricle in
aged animals increases from 5.5% to 12% [96] and it has been postulated
thatﬁbrosis reversibility depends on the degree of cross-linked ECM [97].
From our acute model of ﬁbrosis we found that once the ischemia/
reperfusion ceased, the collagen content in the heart was reduced
within 30 days [98]. As we reported before that elevated collagen
deposition is related to a CD45+ cell inﬂux and their transition
into ﬁbroblasts [5,7,17], a possible strategy would be to reduce the
ability of these cells to transmigrate or differentiate. On the other
hand, in the aging heart dysfunctional mesenchymal ﬁbroblasts dis-
play upregulated collagen synthesis [33]. Collagen synthesis origi-
nating from both these sources of ﬁbroblasts could be modulated
via reduction of prenylation. We discovered that small G proteins
(Rho and Ras) are involved in myeloid and mesenchymal ﬁbroblast-
dependentﬁbrosis respectively. Two enzymes, geranylgeranyltransferase
(GGTase) and farnesyltransferase (FTase) transfer the isoprenyl chain
formed during cholesterol biosynthesis onto a variety of proteins, which
then affects their membrane targeting, cellular localization and protein–
protein interactions [99]. GGTase targets proteins such as Rho, whereas
FTase attaches farnesyl groups to Ras proteins [100]. We found that
genetic inhibition of ROCK-1, a Rho effector, resulted in attenuated
ﬁbrosis and reduced number of myeloid ﬁbroblasts in the heart
[101], suggesting that the use of a speciﬁc GGTase inhibitor could
shut down myeloid cell-dependent ﬁbrosis. Also, the use of an FTase
inhibitor, as we have established before, reduced collagen expression
61K.A. Cieslik et al. / Journal of Molecular and Cellular Cardiology 70 (2014) 56–63in mesenchymal ﬁbroblasts via targeting the Ras/Erk pathway [33].
Taken together we postulate that aged dependent cardiac ﬁbrosis
could be reduced by targeting prenyl transferase pathways (via GGTase
and FTase inhibitors) or prenyl chain biosynthesis (via statins). Use of
statins in treatment of ﬁbrosis has been shown to be beneﬁcial in exper-
imental models [102]. Finally, from the prevention standpoint, treat-
ments or behavioral modiﬁcations that reduce insulin resistance and
lower arterial insulin levels may prevent these changes in MSC that
we have suggested to arise from high insulin levels [33].
7. Conclusions
Wepresent here a new concept of biological cross-talk between ﬁbro-
blasts ofmyeloid andmesenchymal origin that supports the development
of chronic ﬁbrosis in the aging uninjured heart. The evidence suggests
that MCP-1 and TGF-β are major players in this scenario. In the aging
model chemokine synthesis is persistent [5] suggesting a dysregulation
of immune suppression. We demonstrate that unresponsiveness of mes-
enchymal cells to TGF-β due to their defect in TβRI expression results in
insufﬁcient suppression of chemokine synthesis in these cells (MSC and
their ﬁbroblast progeny). This increases the rate of differentiation of
MSC (due to reduction of Nanog) and results in an elevated number of
collagen expressing mesenchymal ﬁbroblasts as observed in our studies
[33]. In addition, resistance to TGF-β in MSC-derived ﬁbroblasts prevents
normal suppression of MCP-1. The resultant chronic expression of MCP-1
derived from stromal cells activates an inﬂuxofmonocytes and their tran-
sition to myeloid ﬁbroblasts [5]. Therefore, ﬁbroblasts from two different
origins contribute to ﬁbrosis in the aging heart.
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